Additionally, a subgroup of acute myeloid leukemia (AML) patients express IRF8-SVs at substantially greater levels (>two-fold) than hematopoietic cells from healthy donors, despite the fact that these splice variants are present in the hematopoietic cells of a normal adult at extremely reduced levels [108,109], and loss of IRF8 inhibits the growth of AML cells, suggesting a dual role for IRF8 as a prognostic factor and therapeutic target in AML [110]. The gene discussed is IRF8; the disease is acute myeloid leukemia.